摘要
依据《中国药品综合评价指南参考大纲》,查阅与纳武利尤单抗和帕博利珠单抗有关的药典、诊疗指南、药品说明书、临床研究文献及官方数据,对两种药品的安全性、有效性、体内药学特性、药品质量、顺应性及药物经济学等8个方面资料进行归纳总结,根据抗PD-1的抗体药物纳武利尤单抗和帕博利珠单抗的安全性、有效性、体内药学特性、药品质量、顺应性及药物经济学等8个方面对药品进行综合评价,纳武利尤单抗和帕博利珠单抗具有良好的临床应用价值。
According to Guideline for Comprehensive Evaluation of Medicine in China,the safety,efficacy,in vivo pharmacological characteristics,drug quality,compliance and pharmacoeconomics of nivolumab and pembrolizumab were summarized.We searched the pharmacopoeia,diagnostic and therapeutic guidelines,drug instructions,clinical research literatures and official data related to nivolumab and pembrolizumab to evaluate above factors of anti-PD-1 antibody drug nivolumab and pembrolizumab,and to provide evidence for rational drug use in clinical drug selection at all levels.Nivolumab and pembrolizumab have good clinical application value.
作者
章越凡
汪硕闻
范国荣
ZHANG Yue-fan;WANG Shuo-wen;FAN Guo-rong(Department of Clinical Pharmacy,Shanghai General Hospital,Shanghai Jiao Tong University,Shanghai 200080)
出处
《中南药学》
CAS
2019年第8期1274-1279,共6页
Central South Pharmacy
基金
上海市卫生计生系统重要薄弱学科建设计划(No.2016ZB0302)
作者简介
章越凡,男,副教授,主要从事临床药学、心血管药理学研究,E-mail:zhangyuefan@126.com;通讯作者:范国荣,男,主任药师,主要从事临床药学、药物分析方面的研究,E-mail:guorfan@163.com
